designer491-3
designer491 / iStockphoto.com
23 January 2018Americas

Celgene reveals plans to acquire Juno for $9bn

Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Asia-Pacific
12 February 2018   Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
31 January 2019   Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

More on this story

Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Asia-Pacific
12 February 2018   Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
31 January 2019   Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

More on this story

Americas
2 February 2018   Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Asia-Pacific
12 February 2018   Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
31 January 2019   Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.